Karsten Bamminger

Karsten Bamminger, holding a BSc and MSc, is an active researcher in the Department of Pharmaceutical Sciences within the Faculty of Life Sciences. His work centers on developing novel radiopharmaceuticals for positron emission tomography (PET), with emphasis on tracer production methodologies and clinical translation.

Education

• Bachelor of Science (BSc)
• Master of Science (MSc)

Research Interests

His expertise spans radiochemistry and molecular imaging, specializing in carbon-11 and fluorine-18 labeled tracers for oncology, neurology, and immuno-oncology applications. Key contributions include optimizing production of [11C]AMT for neuroimaging and developing enzymatic synthesis routes for [18F]FDA. Recent work pioneers small-molecule PD-L1 tracers for immuno-PET, demonstrating strong integration of ligand design with preclinical validation.

Publication Trends

From 2022-2025, his research shows escalating focus on clinical translation of PET tracers. The 2022 [18F]FDA synthesis established efficient enzymatic methods, while the 2023 PD-L1 work introduced ligand-based design principles. The 2025 [11C]AMT adaptation demonstrates robust commercial production protocols, revealing a clear trajectory toward making advanced tracers accessible for human studies in neuro-oncology and immunotherapy monitoring.